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Toll-like receptor (TLR) signaling pathways are strictly coordinated by several mechanisms to regulate adequate innate immune
responses. Recent lines of evidence indicate that the suppressor of cytokine signaling (SOCS) family proteins, originally identiﬁed
asnegative-feedbackregulatorsincytokinesignaling,areinvolvedintheregulationofTLR-mediatedimmuneresponses.SOCS1,a
member of SOCS family, is strongly induced upon TLR stimulation. Cells lacking SOCS1 are hyperresponsive to TLR stimulation.
Thus, SOCS1 is an important regulator for both cytokine and TLR-induced responses. As an immune organ, the liver contains
varioustypesofimmunecellssuchasTcells,NKcells,NKTcells,andKupﬀercellsandiscontinuouslychallengedwithgut-derived
bacterial and dietary antigens. SOCS1 may be implicated in pathophysiology of the liver. The studies using SOCS1-deﬁcient mice
revealed that endogenous SOCS1 is critical for the prevention of liver diseases such as hepatitis, cirrhosis, and cancers. Recent
studies on humans suggest that SOCS1 is involved in the development of various liver disorders in humans. Thus, SOCS1 and
other SOCS proteins are potential targets for the therapy of human liver diseases.
1.Introduction
Proper and coordinated activation of immune signal path-
ways is required for immune responses, including erad-
ication of invading pathogens. Toll-like receptor (TLR)-
and cytokine receptor-mediated signaling are involved in
innate and subsequent adoptive immunity. Aberrant and/or
sustained activation of immune signal pathways may result
in serious disorders such as septic shock, autoimmunity,
and cancer. Thus, immune signals must be tightly regulated
for preventing overactivated immune responses. A number
of regulatory mechanisms on immune signaling pathways
have been reported. A family named suppressor of cytokine
signaling (SOCS) represents a negative regulator for various
cytokine signaling (Table 1)[ 1]. SOCS proteins play impor-
tant roles in maintaining organ homeostasis by preventing
the harmful cytokine responses in various organs [2]. In
t h i sp a p e r ,w ew i l lf o c u so nS O C S 1 ,am e m b e ro fS O C S
family, which plays a key role in the negative regulation of
bothcytokinereceptor-andTLR-mediatedsignaling.Wewill
further discuss the importance of SOCS1 in the pathogenesis
of liver diseases.
2. Regulation of ImmuneSignalPathwaysby
Suppressorof CytokineSignaling(SOCS)
2.1. Inhibition of Cytokine Signaling by SOCS. Cytokine
receptor-mediated signaling critically regulates cellular func-
tions including proliferation, diﬀerentiation, and survival.
SOCS proteins are originally discovered as cytokine-induced
proteins that negatively regulate cytokine receptor signaling
(Table 1)[ 1]. This regulation by SOCS proteins prevents the
harmful overactions mediated by cytokine signaling. The
physiological roles of SOCS proteins have been extensively
investigated by the studies using knockout animals [1, 2].
In mammals, eight members of SOCS proteins (SOCS1
to SOCS7 and CIS) have been reported [1]. These proteins
consist of two conserved motifs, a central SH2 domain and
a C-terminal SOCS box (Figure 1)[ 1]. SOCS1 and SOCS3
possess a kinase-inhibitory region (KIR) domain that is2 Gastroenterology Research and Practice
Table 1: Inducing factors of SOCS family proteins and suppressed signaling by SOCS family proteins (see [1, 3, 4]).
SOCS
family Inducers Suppressed Signaling∗
CIS IL-2, IL-3, EPO, GM-CSF, GH, Prolactin IL-2, IL-3, EPO, GH, Prolactin
SOCS-1
IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-13, IL-15, IL-21,
IFN-α/β,I F N - γ,L I F ,T N F - α,T G F - β, EPO, G-CSF, SCF,
GH, TSH, Prolactin, CNTF, Cardiotrophin, Insulin, LPS,
CpG DNA
IL-2,IL-4,I L - 6 ,IL-7,IL-12,IL-15, IL-21, IFN-α/β, IFN-γ,
LIF, TNF-α, EPO, TPO, TSLP, SCF, GH, Prolactin,
Insulin, LPS, CpGDNA
SOCS-2 IL-2, IL-6, EPO, GH, Prolactin, Insulin, CNTF, IL-6, GH, IGF-I
SOCS-3
IL-1, IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-11, IL-12, IL-22,
IL-23, IL-27, IFN-α/β,I F N - γ,L I F ,T N F - α,T G F - β, EPO,
TPO, G-CSF, GH, TSH, Prolactin, Leptin, CNTF,
Cardiotrophin, EGF, Insulin
IL-1, IL-2, IL-4, IL-6, IL-9, IL-11, IL-27,I F N - α/β,I F N - γ,
LIF, OSM, EPO, G-CSF, GH, Prolactin, Leptin,C N T F ,
Cardiotrophin, Insulin,L P S
SOCS-4 EGF EGF
SOCS-5 EGF IL-4, IL-6, EGF
SOCS-6 SCF, Insulin SCF, Insulin
SOCS-7 Insulin, IGF-1 Insulin
∗Signaling shown in red is demonstrated in the studies using knockout mice.
critical for inhibition of kinase activity [1]. The SH2 domain
of SOCS proteins is a crucial component for association
of SOCS proteins with phosphorylated tyrosine residues on
tyrosine kinases or cytokine receptors [1]. This association
inhibits cytokine signaling by suppressing kinase activity
or by masking docking sites for adaptor molecules on the
receptors. In addition, the SOCS box recruits a complex
containing elongin B, elongin C, cullin-5, RING-box-2, and
E2 ligase via its subdomains, a B/C box and a Cull5 box,
and mediates ubiquitination of SOCS-bound proteins for
proteasomal degradation [5].
Among SOCS proteins, SOCS1 is a prototype molecule.
AnumberofstudiesindicatethatSOCS1preferentiallybinds
to JAK kinases via its SH2 domain and inhibits signaling
by shutting down JAK kinase activity via the KIR domain
as well as by promoting JAK degradation via the SOCS box
[2]. Given the role of JAK kinases in signaling of cytokine
receptors, mice lacking SOCS1 exhibit hypersensitivity to a
variety of cytokines, including IFN-α,I F N - γ,I L - 2 ,I L - 4 ,I L -
7, IL-12, and IL-15 (Table 1)[ 1, 2]. SOCS1 deﬁcient mice
are born normally, but die within three weeks of age due
to lymphocyte-dependent multiorgan inﬂammatory disease
[1, 2].
2.2. SOCS1 Negatively Regulates TLR Signaling. The expres-
sion of SOCS1 is induced by various cytokines, including
IL-4 and IFN-γ, and also by TLR ligands, such as LPS
and CpG-DNA (Table 1)[ 3]. TLR ligands induce SOCS1
expression directly through the activation of early growth
response-1 (Egr-1) [6] and/or indirectly through cytokines,
including IL-6 and IFN-β induced by initial TLR signaling
[3]. This ﬁnding raises the possibility that SOCS1 regulates
TLR signaling. In accordance with this, enforced expression
of SOCS1 results in reduced response of cells to TLR ligands.
More importantly, SOCS1 deﬁcient mice are hypersensitive
not only to cytokines but also to TLR ligands [7, 8]. Upon
stimulation with LPS, a TLR4 ligand, or CpG-DNA, a TLR9
KIR
SH2 domain SOCS box
CIS, SOCS2
SOCS1, SOCS3
SOCS4, SOCS5, SOCS6, SOCS7
SH2 domain SOCS box
SH2 domain SOCS box
Figure 1: Schematic structure of SOCS proteins. SOCS proteins are
structurallycharacterizedbyacentralSH2domain,adockingmotif
to tyrosine-phosphorylated proteins, and a c-terminal SOCS box
that recruits Elongin B/C complex. SOCS1 and SOCS3 also possess
a KIR domain, which plays an important role in inhibition of JAK
kinase activity. The length of N-terminal domain varies between
SOCS proteins and SOCS4-7 possesses relatively long N-terminal
domain.
ligand, SOCS1 deﬁcient macrophages produce an increased
amount of inﬂammatory cytokines, including TNF-α,I L -
6, and IL-12. Furthermore, LPS tolerance, refractoriness to
second challenge with LPS after initial LPS exposure, is not
induced in SOCS1 deﬁcient mice. Although IFN-γ/STAT1
pathway is the major target for SOCS1, SOCS1 deﬁcient cells
lacking IFN-γ or STAT1 still exhibited enhanced response to
LPS [7, 8]. This suggests that the hypersensitivity of SOCS1
deﬁcient cells to LPS is largely due to their dysregulated
response to TLR signaling, but not IFN signaling secondarily
induced by TLR signaling. Thus, SOCS1 directly induces the
negative regulation of TLR signaling [3, 5].
3. Mechanisms of Negative Regulation of
TLR Signalingby SOCS1
SOCS1-mediated negative regulation of TLR signaling has
been reported by a number of studies [3]. Although the
major mechanism by which SOCS1 regulates TLR-mediatedGastroenterology Research and Practice 3
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Figure 2: Proposed inhibitory mechanisms of SOCS1 on TLR signaling. The absence of SOCS1 results in heightened response to TLR
ligands. Possible mechanisms of action of SOCS1 proposed so far are outlined here. Upon induction, SOCS1 binds to Mal/TIRAP and
mediates its degradation via proteasomal pathway (1). SOCS1 binds to IRAK and may modulate its activity (2). SOCS1 binds to p65 subunit
of NFκB and targets it for proteasomal degradation (3). SOCS1 inhibits JAK2 activated directly after TLR stimulation (4). SOCS1 regulates
TLR-mediated response indirectly by inhibition of TLR-induced cytokines such as IFN-β (5).
responses remains a matter of debate, several mechanisms
have been proposed as outlined below (Figure 2).
3.1. Regulation of TLR-Mediated Cytokine Signaling by
SOCS1. The activation of TLR signaling results in the
induction of inﬂammatory cytokines such as TNF-α,I L -
6, and IFN-α/β. Given the role of SOCS1 in inhibition of
cytokine-mediated signaling, one of the most representative
functions of SOCS1 is to regulate intracellular signaling
activated by cytokines which are induced by initial TLR
signaling. Indeed, several reports demonstrated that the
signaling of IFN-β induced by the ﬁrst TLR stimulation is
the critical target of SOCS1 [9–11]. In accordance with this,
SOCS1 deﬁcient cells are highly sensitive to type I IFNs, and
lethal disease in SOCS1 deﬁcient mice is partly mediated by
the dysregulation of IFN-α/β signaling [12].
3.2.AssociationofIRAKwithSOCS1. Twoindependentstud-
ies have shown that LPS-induced proinﬂammatory cytokine
production and NF-κB activation are inhibited in cells over-
expressing SOCS1 [7, 8]. Among signaling molecules that
bridge between TLR and NF-κB, IL-1 receptor-associated
kinase 1 (IRAK1) is a target of SOCS1. SOCS1 directly
associates with IRAK1 via its SH2 domain [7].
3.3. Regulation of Mal/TIRAP Protein Expression by SOCS1.
The TLR adaptor molecule Mal/TIRAP is also a target
of SOCS1 [13]. TLR stimulation induces Btk-dependent
tyrosine-phosphorylationofMalandgeneratesabindingsite
for SH2 domain of SOCS1. Subsequent interaction between
SOCS1 and Mal induces ubiquitination and proteasomal
degradation of Mal, resulting in abrogation of TLR/Mal-
dependent NF-κBa c t i v a t i o n[ 13] .Ar e c e n tr e p o rth a ss h o wn
that SOCS1 also regulates the intracellular protein levels of
Mal in hepatocytes, which inhibit intracellular uptake of LPS
by hepatocytes [14].
3.4. Regulation of NF-κBA c t i v a t i o nb yS O C S 1 .SOCS1 also
regulates TLR-induced NF-κB activation by direct interac-
tion with p65 subunit of NF-κB upon stimulation with
LPS. SOCS1 downregulates p65 protein levels by ubiquitin-
mediated degradation of p65 [15].
3.5. Regulation of TLR-Induced JAK2 Activation by SOCS1.
Several reports demonstrated that JAK2 in macrophages
contributes to the induction of proinﬂammatory cytokines
by LPS stimulation [16, 17]. Since JAK2 is a major target of
SOCS1, it is likely that the inhibitory eﬀect of SOCS1 on LPS
signaling is partially due to the binding of SOCS1 to JAK2 in
TLR4/JAK2 pathway [17].
4. SOCS1 inLiverPathophysiology
SOCS1 expression is induced in hepatocytes by a variety
of exogenous stimulation such as IL-6 and IFN-γ during
liver pathobiology. SOCS1 regulates various intracellular
signaling pathways in hepatocytes, which may modulate liver
pathophysiology (summarized in Table 2).
4.1. Protective Roles of SOCS1 in Hepatitis. SOCS1 deﬁcient
mice display a fatal neonatal disease, which is characterized
by aberrant activation of T cells and multiple organ injury.
Hepatic inﬂammation accompanied by fatty degeneration
and hepatocyte necrosis is the major cause of the death in
SOCS1 deﬁcient mice. This fulminant hepatitis in SOCS1
deﬁcient mice is due to exacerbated activation of hepatic4 Gastroenterology Research and Practice
Table 2: Proposed involvement of SOCS1 in liver pathophysiology.
Mechanism for SOCS1
dysregulation
Pathogenic
consequences
in liver
Increased
SOCS1
(1) Excessive stimulation with
cytokines/TLR ligands
Insulin
resistance
Reduced liver
regeneration
Reduced
SOCS1
(1) CpG methylation Hepatitis
(2) Promoter polymorphism? Liver ﬁbrosis
(3) Genetic mutation? Hepatocellular
carcinoma
lymphocytes, including NKT cells [18], and increased sensi-
tivity of hepatocytes to inﬂammatory cytokines such as IFN-
γ [19].
SOCS1 expression is also important for suppression of
hepatitis in adult mice. Concanavalin A- (ConA-) induced
hepatitis is a murine model of T cell-mediated acute
hepatitis. In this model, IFN-γ/STAT1 pathway accelerates
liver injury, while IL-6/STAT3 ameliorates disease [20]. Both
SOCS1 and SOCS3 are induced in the liver after ConA injec-
tion [20] and provide reciprocal regulation in IFN-γ/STAT1
and IL-6/STAT3 pathway [21]. Compared to wild type
mice, mice with speciﬁc deletion of SOCS1 in hepatocytes
(hepatocyte-speciﬁc SOCS1 conditional KO mice) exhibit
severeConA-inducedhepatitiswithincreasedmortality[22].
Conversely, SOCS3 conditional KO mice exhibit reduced
liver injury [23]. Collectively, SOCS1 expression in the liver
prevents fatal hepatitis via the suppression of exacerbated
liver inﬂammation.
4.2.ProtectiveRolesofSOCS1inLiverFibrosisandCarcinoma.
Dimethylnitrosamin (DMN) treatment induces liver ﬁbrosis
in mice. SOCS1 heterozygous mice exhibit enhanced liver
damage, severe liver ﬁbrosis, and increased mortality after
the treatment with DMN, compared to wild type mice.
After treatment with diethylnitrosamin (DEN), a chemical
agent that induces hepatocellular carcinoma (HCC), SOCS1
heterozygous mice developed more tumors than wild type
mice [24]. These ﬁndings suggest that endogenous SOCS1
prevents liver ﬁbrosis and hepatocarcinogenesis.
4.3. SOCS Proteins Regulate Liver Regeneration. MyD88-
dependent innate immune signaling induces inﬂammatory
cytokines, including TNF-α and IL-6, to initiate liver
regeneration after partial hepatectomy (PH) [25, 26]. SOCS
genes are induced through MyD88 during liver regener-
ation [26, 27]. Produced IL-6 during liver regeneration
activates STAT3, which is an important component to
induce hepatocyte proliferation as well as a crucial target
of SOCS1 and SOCS3 in hepatocytes. Enforced SOCS1 or
SOCS3 expression in hepatocytes inhibits STAT3 activation
and hepatocyte proliferation induced by IL-6, hepatocyte
growth factor (HGF), and epidermal growth factor (EGF),
which results in the suppression of liver regeneration [28,
29]. Mice lacking SOCS3 in hepatocytes exhibit enhanced
STAT3 activation, hepatocyte proliferation, and liver weight
restoration after PH [30]. Thus, SOCS molecules negatively
regulate physiological proliferation of hepatocytes after PH.
4.4. Role of SOCS Proteins in Metabolic Syndrome. Proin-
ﬂammatory cytokines are key factors to develop metabolic
syndrome, including insulin resistance. Several lines of
evidence suggest that inﬂammatory cytokines exacerbate
insulin resistance via SOCS protein induction in the liver
[31]. The expression of SOCS1 and SOCS3 is increased in
a murine model of obesity [32]. In vitro experiments using
cellsoverexpressingSOCSsuggestthatmembersoftheSOCS
family, such as SOCS1, SOCS3, and SOCS6, inhibit insulin
signaling directly by interacting with insulin receptor and/or
IRS [31]. In vivo, Adenoviral overexpression of SOCS1 or
SOCS3 in the liver enhances insulin resistance and fatty acid
synthesis [32]. In addition, cells lacking SOCS1, SOCS3, or
SOCS7 exhibit increased sensitivity to insulin [33–36]. These
results suggest that the induction of SOCS1 and other SOCS
proteins in hepatocytes plays an important role in hepatic
metabolism and pathogenesis of metabolic syndrome.
5.SOCS1 inHumanLiverDisease
Studies using animal models suggest that inadequate induc-
tion or impaired expression of SOCS1 may induce liver
diseases in humans. Thus far, although inactivating muta-
tions in SOCS1 gene were detected in a subset of lymphoma
cells [2], such mutations have not been observed in hep-
atic disorders. Nevertheless, previous studies have shown
that SOCS1 CpG islands in human primary hepatocellular
carcinomas (HCCs) are frequently methylated, suggesting
that the epigenetic silencing of SOCS1 participates in tumor
growth of HCCs [37, 38]. Interestingly, SOCS1 methylation
is highly prevalent in HCC with HCV infection but not with
HBV infection [39]. In addition, SOCS1 gene methylation
is also detected in patients with hepatitis C [24]. These
resultssuggestthatendogenousSOCS1isatumorsuppressor
of HCCs and epigenetic modiﬁcation of SOCS1 expression
by HCV infection leads to the progression of hepatic
inﬂammation and the progression of HCCs.
On the other hand, genetic polymorphism on SOCS1
promoter region may impair SOCS1 induction. Indeed, a
recent study demonstrated that the SOCS1 polymorphisms
in Caucasians are associated with alteration in body mass
index [40]. Although it remains unclear whether SOCS1
polymorphisms modify SOCS1 expression in the liver and
SOCS1polymorphismsinﬂuenceinsulinsensitivityandlipid
metabolism, SOCS1 polymorphisms might be associated
with metabolic syndrome in humans.
6.SOCS3 inTLR SignalingandHuman
LiverDiseases
Overexpression studies have shown that both SOCS1 and
SOCS3 exhibit similar inhibitory functions on various
cytokine signaling in vitro (Table 1). However, SOCS1 andGastroenterology Research and Practice 5
SOCS3 are not functionally interchangeable. Interestingly,
SOCS3 deﬁcient mice are embryonic lethal, due to pla-
cental insuﬃciency as a result of hypersensitivity to LIF
[1]. Additional studies using SOCS3 conditional KO mice
revealedthatSOCS3isrequiredfornegativeregulationofIL-
6, leptin, and G-CSF signaling [3]. These results indicate that
SOCS3 has nonredundant physiological inhibitory functions
in cytokine signaling, including IL-6, LIF, leptin, and G-CSF
signaling.
Several reports have shown that SOCS3 regulates TLR
signaling. LPS treatment strongly induces SOCS3 expres-
sion in macrophages and hepatocytes [41]. In addition,
like SOCS1, SOCS3 inhibits TLR-mediated responses [2].
However, the action of SOCS3 in TLR signaling may be
complex,becausethereareconﬂictingreportsdescribingthat
SOCS3 has little or even enhancing eﬀect on TLR response
[11, 42]. Moreover, mice lacking SOCS3 in myeloid cells are
resistant to LPS-induced lethal shock [22]. Nevertheless, it is
of interest to elucidate the precise function of SOCS3 in TLR
response, since accumulating evidence suggests that SOCS3
is important for the pathology of hepatic diseases.
As described earlier, SOCS3 is induced in the liver
during liver regeneration. Hepatocyte proliferation and
hepatic weight restoration are enhanced in hepatocyte-
speciﬁc SOCS3 knockout mice [30]. ConA or DMN treat-
ment induces excessive ﬁbrosis in hepatocyte-speciﬁc SOCS3
knockout mice, although hepatic inﬂammation is amelio-
rated in these mice [43]. In addition, hepatocyte-speciﬁc
SOCS3 knockout mice develop more liver tumors than wild
type mice after DEN treatment [23, 30]. Stimulation of
cytokines such as IL-6 induces constitutive activation of
STAT3 in SOCS3 deﬁcient hepatocytes. Given the crucial
role of IL-6/STAT3 pathway in HCC development [44, 45],
this might be the mechanism of enhanced tumorigenesis in
hepatocyte-speciﬁc SOCS3 knockout mice. These ﬁndings
suggest that SOCS3 in hepatocytes regulates hepatocyte
homeostasis, including survival and proliferation, which
further contributes to the regulation of ﬁbrosis and car-
cinogenesis in the liver. Notably, SOCS3 in hepatic T cells
may have a diﬀerent role in the regulation of hepatic
inﬂammation. Conditional deletion of SOCS3 in T and
NKT cells exacerbates ConA-induced hepatitis [46], while
transgenic overexpression of SOCS3 in T and NKT cells
[46, 47] or intraperitoneal administration of cell-penetrating
SOCS3 in mice [48] prevents ConA-induced liver injury.
In humans, SOCS3 is implicated in HBV- and HCV-
induced pathology of the liver. In contrast to the observation
in SOCS1, SOCS3 expression is upregulated in the livers
of HBV [49] and HCV patients [23, 50]. HBV X protein
enhances SOCS3 expression in hepatocytes [51]. HCV core
protein induces SOCS3 expression in hepatoma cells [52,
53], while it inhibits SOCS1 expression [54]. Enhanced
SOCS3 expression may prevent HCC development, but may
induce insulin resistance [53], immune dysfunction [49],
and refractoriness to IFN therapy [52]. Interestingly, in
the liver of HCV patients with HCC, SOCS3 expression
is increased in noncancerous region but remained low in
HCC region [23, 30]. This observation suggests that SOCS3
in hepatocytes is somehow silenced during tumorigenesis
in HCV patients. Thus, while further studies are required,
SOCS3couldbeanattractivetargetforthetherapyofhuman
liver diseases.
7. Conclusion
Although the mechanism by which SOCS1 inhibits TLR
signaling is not fully understood, accumulating evidence
indicates that the absence of SOCS1 strongly enhances TLR
responses. Since SOCS1 is induced in the liver by multiple
factorsincluding cytokines,TLRligands,andinsulin, SOCS1
should regulate both cytokine and TLR signaling under
various physiological and/or pathological conditions. In
accordance with this, mice lacking SOCS1 are sensitive to a
variety of liver diseases including hepatitis, liver cirrhosis,
and HCC. Moreover, silenced SOCS1 expression due to
CpG methylation is involved in pathogenesis of hepatitis C,
HCC, and many other types of human cancers [2]. It is
also possible that impaired SOCS1 expression may underlie
the pathogenesis of other human liver diseases induced by
infection, autoimmunity, drugs, and alcohol. In contrast,
it has been shown that an excessive induction of SOCS1
by TLR ligands and cytokines contributes to the alteration
of insulin sensitivity in metabolic syndrome. Future studies
on SOCS1 and other SOCS proteins will provide insight
into the pathobiology of human liver diseases and develop
new strategies for the treatment of acute and chronic liver
diseases.
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